Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 313

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)

Open access
Seifert, Robert, Emmett, Louise, Rowe, Steven P., Herrmann, Ken, Hadaschik, Boris, Calais, Jeremie, Giesel, Frederik L., Reiter, Robert, Maurer, Tobias, Heck, Matthias, Gafita, Andrei, Morris, Michael J., Fanti, Stefano, Weber, Wolfgang A., Hope, Thomas A., Hofman, Michael S., Fendler, Wolfgang Peter, Eiber, Matthias·2023·European Urology

Abstract

CONTEXT: Prostate-specific membrane antigen (PSMA) targeting positron emission tomography (PET) is emerging to become a reference imaging tool for the staging and restaging of patients with prostate cancer for both clinical routine and trials. The prostate cancer molecular imaging standardized evaluation (PROMISE) criteria have been proposed as a framework for whole-body staging (molecular imaging TNM staging, denoted miTNM staging) to describe the prostate cancer disease extent on PSMA-PET. OBJECTIVE: To create a comprehensive and integrated framework for PSMA-PET image interpretation and reporting. EVIDENCE ACQUISITION: We propose the PROMISE V2 framework, which integrates an updated miTNM system, improved assessment of local disease, and a slightly modified PSMA-expression score for clinical routine. We have added a response monitoring framework defining qualitative and quantitative parameters to be recorded for a longitudinal assessment in clinical trials. EVIDENCE SYNTHESIS: Lu-PSMA radioligand therapy. The proposed imaging parameters recorded for response assessment in clinical trials can be utilized to determine response according to PSMA-PET progression (PPP) or Response Evaluation Criteria in PSMA-PET/Computed Tomography (RECIP) frameworks, but also future response criteria. CONCLUSIONS: PROMISE V2 offers standardized reporting of disease extent for clinical routine and research. Parameters recorded within clinical trials facilitate objective response assessment. PATIENT SUMMARY: Prostate-specific membrane antigen (PSMA) targeting positron emission tomography (PET) has become a standard imaging examination for prostate cancer. We propose a comprehensive framework for the analysis and reporting of PSMA-PET findings that will improve the communication between imaging experts and uro-oncologists.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.eururo.2023.02.002

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Cited by

See all 313

Metadata

Authors
Seifert, R., Emmett, L., Rowe, S. P., Herrmann, K., Hadaschik, B., Calais, J., Giesel, F. L., Reiter, R., Maurer, T., Heck, M., Gafita, A., Morris, M. J., Fanti, S., Weber, W. A., Hope, T. A., Hofman, M. S., Fendler, W. P., & Eiber, M.
Venue
European Urology
Publisher
Elsevier BV
Published
2023-05
Volume
83
Issue
5
Pages
405-412
ISSN
0302-2838 (ISSN-L)
OpenAlex
W4327694432
Cited by
313
References
41
FWCI
49.72
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2). https://app.cochat.ai/papers/10.1016/j.eururo.2023.02.002
The paper
Seifert, R., Emmett, L., Rowe, S. P., Herrmann, K., Hadaschik, B., Calais, J., Giesel, F. L., Reiter, R., Maurer, T., Heck, M., Gafita, A., Morris, M. J., Fanti, S., Weber, W. A., Hope, T. A., Hofman, M. S., Fendler, W. P., & Eiber, M. (2023). Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2). European Urology. https://doi.org/10.1016/j.eururo.2023.02.002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.